Experimental treatments for the hepatitis C virus could eliminate the need for interferon therapy in previously untreated patients, according to data from two studies. In one study, the nucleotide polymerase inhibitor sofosbuvir and ribavirin were administered for up to 12 weeks and appeared effective at treating patients regardless of virus genotype as long as they had not previously taken interferon and ribavirin. In the second study, researchers found that a combination of ABT-450, ABT-333 and ribavirin yielded promising results for patients with genotype 1 virus who had not been previously treated. The findings may help advance the development of an interferon-free, all-oral treatment protocol, researchers said.

Related Summaries